このページの翻訳は実験的なもので、現在開発中です。お待ちしております
874 株式概要
広州白雲山医薬集団有限公司は、その子会社とともに、中華人民共和国および国際的な中国特許および西洋医薬品、化学原料、天然および生物学的医薬品、化学原料の中間体の研究、開発、製造、販売を行っている。
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited 競合他社
価格と性能
過去の株価 | |
---|---|
現在の株価 | HK$17.34 |
52週高値 | HK$24.20 |
52週安値 | HK$16.62 |
ベータ | 0.55 |
11ヶ月の変化 | -10.62% |
3ヶ月変化 | -17.03% |
1年変化 | -22.42% |
33年間の変化 | -12.51% |
5年間の変化 | -34.07% |
IPOからの変化 | 1,194.03% |
最新ニュース
Earnings Report: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Missed Revenue Estimates By 8.1%
Sep 04A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Jul 15Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
Jun 26Recent updates
Earnings Report: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Missed Revenue Estimates By 8.1%
Sep 04A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Jul 15Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
Jun 26Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing
Jan 09With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Nov 28A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 15We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Oct 19Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes
Oct 03Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?
Aug 15Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall
Jul 02Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jun 01Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors
May 01The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing
Mar 28Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Feb 23With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Jan 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger
Dec 24Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 24Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?
Nov 11Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price
Apr 29Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Apr 10We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Jan 09Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet
Oct 11Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jul 12Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?
Apr 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 08These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well
Mar 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain
Feb 11Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?
Jan 26Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?
Jan 06Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Dec 23Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 26株主還元
874 | HK Healthcare | HK 市場 | |
---|---|---|---|
7D | 0.5% | 2.9% | 4.1% |
1Y | -22.4% | -37.6% | 0.9% |
業界別リターン: 874過去 1 年間で-31.1 % の収益を上げたHong Kong Healthcare業界を上回りました。
リターン対市場: 874は、過去 1 年間で3.3 % のリターンを上げたHong Kong市場を下回りました。
価格変動
874 volatility | |
---|---|
874 Average Weekly Movement | 3.6% |
Healthcare Industry Average Movement | 5.4% |
Market Average Movement | 6.3% |
10% most volatile stocks in HK Market | 13.3% |
10% least volatile stocks in HK Market | 3.3% |
安定した株価: 874の株価は過去 3 か月間にわたって変動しています。
時間の経過による変動: 874の 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。
会社概要
設立 | 従業員 | CEO(最高経営責任者 | ウェブサイト |
---|---|---|---|
1997 | 28,760 | Hong Li | www.gybys.com.cn |
広州白雲山医薬集団有限公司は、その子会社とともに、中華人民共和国および国際的な中国特許および西洋医薬品、化学原料、天然および生物学的医薬品、化学原料の中間体の研究、開発、製造、販売を行っている。同社は、Great Southern TCM、Great Commerce、Great Health、その他のセグメントを通じて事業を展開している。また、西洋薬、中国薬、医療器具、医薬品、医療機器、ヘルスケア製品の卸売、小売、販売、輸出入、飲料、食品、ヘルスケア製品などの研究開発、製造、販売、包装済み食品、乳製品などの製造、販売も行っており、ハーブティー、錠剤、カプセル、トローチ、亀の子ゼリーなども提供している。また、医療サービス、健康管理、健康維持、高齢者ケアなどの健康産業への投資、リース、商業、健康、広告、荷揚げ、倉庫サービスなども提供している。小売チェーン薬局や小売店を通じて事業を展開している。旧社名は広州薬業有限公司(Guangzhou Pharmaceutical Company Limited)で、2013年8月に広州白雲山医薬集団有限公司(Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited)に社名変更した。Guangzhou Baiyunshan Pharmaceutical Holdings Company Limitedは1997年に設立され、中国の広州に本社を置く。
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited 基礎のまとめ
874 基礎統計学 | |
---|---|
時価総額 | HK$42.71b |
収益(TTM) | HK$4.19b |
売上高(TTM) | HK$84.62b |
6.7x
PER(株価収益率0.3x
P/Sレシオ874 は割高か?
公正価値と評価分析を参照収益と収入
874 損益計算書(TTM) | |
---|---|
収益 | CN¥76.59b |
売上原価 | CN¥62.98b |
売上総利益 | CN¥13.61b |
その他の費用 | CN¥9.81b |
収益 | CN¥3.79b |
直近の収益報告
Jun 30, 2024
次回決算日
該当なし
一株当たり利益(EPS) | 2.33 |
グロス・マージン | 17.77% |
純利益率 | 4.95% |
有利子負債/自己資本比率 | 34.5% |
874 の長期的なパフォーマンスは?
過去の実績と比較を見る